UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securiti ...

Luisrojasstock/iStock via Getty Images Galectin Therapeutics (NASDAQ:GALT) has a major milestone approaching towards the end of 2024, which is going to be the release of data from the phase 2b NAVIGATE study. This particular study is exploring the use of Belapectin for the prevention of esophageal varices in patients with NASH cirrhosis. I believe that investors should focus on this biotech, because it is gearing up to report topline results from the phase 2b/3 NAVIGATE study in Q4 of 2024. This is goin ...

NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development. Dr. Jamil brings to Galectin almost two decades of experience in clinical development across the biotechnology industry. "We are pleased to welcome Khurram to the Galectin team at such a meaningful time of our development program" said Pol F. Boudes, M.D ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. Nevada 04-3562325 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) 4960 P ...

GALECTIN THERAPEUTICS INC. Nevada 04-3562325 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 4960 Peacht ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (678) 620 -3186 (Registrant's Telephone Number, Including Area Code) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. Nevada 04-3562325 (State or other jurisdict ...

Financial Performance - The company has not generated any revenues to date and is dependent on additional outside capital for future operations [186]. - Net cash used in operations increased by $6,748,000 to $31,056,000 in 2022 compared to $24,308,000 in 2021, mainly due to increased research and development activities [187]. - Net cash used in operations increased by $3,707,000 to $24,308,000 for 2021, compared to $20,601,000 for 2020, primarily due to increased research and development activities related to the NAVIGATE clinical trial [190]. - Net cash provided by financing activities was $36,814,000 during 2021, a significant increase from $263,000 in 2020, driven by proceeds from related-party convertible notes and common stock warrants [191]. - The company received $30,000,000 from three related-party convertible notes payable in 2021 [191]. Research and Development - Research and development expenses increased by 33% from $23,818,000 in 2021 to $31,737,000 in 2022, primarily due to costs related to the NAVIGATE clinical trial activities [174]. - Clinical program expenses increased due to costs related to NAVIGATE clinical trial activities and preparations [177]. - The company completed two Phase 1 clinical studies and two Phase 2 clinical studies for its lead product candidate, belapectin [173]. - Research and development expenses are charged as incurred, including costs related to clinical trials and preclinical studies, with significant factors for accruals including patient enrollment and active clinical sites [199]. Cash and Liquidity - As of December 31, 2022, the company had $18.6 million in unrestricted cash and cash equivalents, along with $50 million available under a line of credit [186]. - The company believes it has sufficient cash to fund operations at least through December 31, 2024, but will require more cash thereafter [186]. - The company has not created any off-balance sheet entities for raising capital or incurring debt, ensuring no material impact on liquidity or capital resources [196]. Expenses - General and administrative expenses rose by 4% from $6,361,000 in 2021 to $6,615,000 in 2022, attributed to an increase in non-cash stock-based compensation [178]. - Other income and expense for 2022 included $52,000 of interest income, offset by $1,033,000 in interest expense and amortization of debt discounts [179]. - Stock-based compensation cost is measured at the grant date based on fair value and recognized as an expense over the service period, with estimates of forfeitures included [200]. Operational Activities - The company entered into an operating lease for office space in Norcross, GA, with an average rate of approximately $4,250 per month, starting March 1, 2022 [193]. - The company has engaged outside vendors for clinical trial services, which are typically cancellable on 30 days' notice [195]. - The company monitors patient enrollment levels and related activities through internal reviews and discussions with contract research organizations [199].

Corporate Overview October 2022 2022 Galectin Therapeutics | NASDAQ: GALT www.galectintherapeutics.com Forward-looking statements This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. Nevada 04-3562325 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) 4960 P ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. Nevada 04-3562325 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) 4960 Peacht ...